Omixon is a global molecular diagnostics company headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories.Omixon is transforming molecular biology innovations into state-of-the-art products in transplant diagnostics which could facilitate genetic testing solutions for transplant centers.Omixon enables histocompatibility laboratories to bring the benefits of new technologies to improve transplant outcomes. Omixon introduced its first successful commercial NGS-based HLA typing kit and HLA Twin software in 2014. Holotype HLA, an NGS-based HLA genotyping product, delivers the most accurate high-resolution HLA genotyping available and is used in more than 60+ laboratories worldwide.Omixon's research software, the HLA Explore, analyzes data from any sequencing technology and determines HLA genotypes from whole exome/genome sequencing data.Omixon uses its multidisciplinary competence ranging from bioinformatics, through software engineering to molecular diagnostics to design its products.Omixon maintains an active research program with a product pipeline focused on pre- and post-transplantation, and HLA genotyping applications beyond transplantation.